Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
KERX's Cash to Debt is ranked higher than
96% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. KERX: No Debt )
KERX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.78
KERX's Equity to Asset is ranked higher than
81% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. KERX: 0.78 )
KERX' s 10-Year Equity to Asset Range
Min: -0.06   Max: 0.93
Current: 0.78

-0.06
0.93
Interest Coverage No Debt
KERX's Interest Coverage is ranked higher than
96% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KERX: No Debt )
KERX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 19.20
M-Score: -3.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -871.01
KERX's Operating margin (%) is ranked higher than
58% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. KERX: -871.01 )
KERX' s 10-Year Operating margin (%) Range
Min: -15010.67   Max: 38.97
Current: -871.01

-15010.67
38.97
Net-margin (%) -866.82
KERX's Net-margin (%) is ranked higher than
58% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. KERX: -866.82 )
KERX' s 10-Year Net-margin (%) Range
Min: -13813.48   Max: 41.62
Current: -866.82

-13813.48
41.62
ROE (%) -94.40
KERX's ROE (%) is ranked higher than
60% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. KERX: -94.40 )
KERX' s 10-Year ROE (%) Range
Min: -429.23   Max: 68.51
Current: -94.4

-429.23
68.51
ROA (%) -78.54
KERX's ROA (%) is ranked higher than
57% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. KERX: -78.54 )
KERX' s 10-Year ROA (%) Range
Min: -323.38   Max: 31.09
Current: -78.54

-323.38
31.09
ROC (Joel Greenblatt) (%) -13257.79
KERX's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. KERX: -13257.79 )
KERX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -46369.35   Max: 7114.49
Current: -13257.79

-46369.35
7114.49
EBITDA Growth (3Y)(%) 17.20
KERX's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. KERX: 17.20 )
KERX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.1   Max: 71.3
Current: 17.2

-45.1
71.3
EPS Growth (3Y)(%) 18.30
KERX's EPS Growth (3Y)(%) is ranked higher than
89% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. KERX: 18.30 )
KERX' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.5   Max: 60
Current: 18.3

-44.5
60
» KERX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

KERX Guru Trades in Q4 2013

Jim Simons Sold Out
» More
Q1 2014

KERX Guru Trades in Q1 2014

Jim Simons 18,700 sh (New)
Steven Cohen 1,525,058 sh (New)
Pioneer Investments 284,299 sh (New)
Seth Klarman 6,310,850 sh (New)
» More
Q2 2014

KERX Guru Trades in Q2 2014

Seth Klarman 10,539,986 sh (+67.01%)
Steven Cohen 1,247,000 sh (unchged)
Jim Simons Sold Out
Pioneer Investments Sold Out
» More
Q3 2014

KERX Guru Trades in Q3 2014

Seth Klarman 18,300,000 sh (+73.62%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2014-09-30 Add 73.62%1.87%$12.71 - $18.19 $ 13.07-15%18300000
Seth Klarman 2014-06-30 Add 67.01%1.04%$12.11 - $17.03 $ 13.07-8%10539986
Seth Klarman 2014-03-31 New Buy2.6%$12.16 - $16.88 $ 13.07-13%6310850
John Burbank 2012-12-31 Sold Out 0.06%$2.31 - $3.14 $ 13.07380%0
John Burbank 2012-09-30 New Buy0.06%$1.79 - $2.83 $ 13.07528%500000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Keryx Biopharmaceuticals Inc

Baupost’s Seth Klarman Buys Cheniere Energy, Ocwen Financial, Antero Resources, Sells Boyd Gaming, Theravance
Renowned value investor, hedge fund manager Seth Klarman (Trades, Portfolio) just reported his third quarter portfolio. Seth Klarman (Trades, Portfolio) buys Cheniere Energy Inc, Ocwen Financial Corp, Antero Resources Corp, Veritiv Corp, Keryx Biopharmaceuticals Inc, eBay Inc, PBF Energy Inc, Forward Pharma AS, PBF Energy Inc, Atara Biotherapeutics Inc, sells Boyd Gaming Corporation, Theravance Inc, Syneron Medical Ltd during the 3-months ended 09/30/2014, according to the most recent filings of his investment company, The Baupost Group. As of 09/30/2014, The Baupost Group owns 27 stocks with a total value of $5.7 billion. These are the details of the buys and sells. Read more...
Seth Klarman’s The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, Sells BP, Theravance
Legendary value investor, hedge fund manager Seth Klarman (Trades, Portfolio) just reported his second quarter portfolio. Seth Klarman (Trades, Portfolio) buys eBay Inc, SunEdison Semiconductor Ltd, Keryx Biopharmaceuticals Inc, Kosmos Energy Ltd, Boyd Gaming Corporation, Triquint Semiconductor, RF Micro Devices Inc, Cheniere Energy Inc, Viasat Inc, Veritiv Corp, Veritiv Corp, sells BP PLC, Theravance Inc during the 3-months ended 06/30/2014, according to the most recent filings of his investment company, The Baupost Group. As of 06/30/2014, The Baupost Group owns 24 stocks with a total value of $6.1 billion. These are the details of the buys and sells. Read more...
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals
The Baupost Group’s Seth Klarman (Trades, Portfolio) has purchased a new holding that constitutes more than 5% of the company, requiring reporting during the quarter and appearing on GuruFocus RealTime Picks. The purchase was of 9,151,600 shares of Keryx Biopharmaceuticals (KERX), which represents 10.07% of the company’s shares outstanding. Read more...
Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD
According to GuruFocus Insider Data, the largest insider sells during the past week were: Keryx Biopharmaceuticals Inc., Oracle Corporation, Qualcomm Inc. and Gilead Sciences Inc. Read more...

Ratios

vs
industry
vs
history
Forward P/E 26.67
KERX's Forward P/E is ranked higher than
93% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KERX: 26.67 )
N/A
P/B 12.30
KERX's P/B is ranked higher than
64% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. KERX: 12.30 )
KERX' s 10-Year P/B Range
Min: 1.88   Max: 49
Current: 12.3

1.88
49
P/S 120.00
KERX's P/S is ranked higher than
68% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. KERX: 120.00 )
KERX' s 10-Year P/S Range
Min: 1.1   Max: 1911
Current: 120

1.1
1911
EV-to-EBIT -12.45
KERX's EV-to-EBIT is ranked higher than
66% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KERX: -12.45 )
KERX' s 10-Year EV-to-EBIT Range
Min: -29.7   Max: 54.6
Current: -12.45

-29.7
54.6
Current Ratio 4.34
KERX's Current Ratio is ranked higher than
72% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. KERX: 4.34 )
KERX' s 10-Year Current Ratio Range
Min: 1.88   Max: 106.93
Current: 4.34

1.88
106.93
Quick Ratio 4.31
KERX's Quick Ratio is ranked higher than
73% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. KERX: 4.31 )
KERX' s 10-Year Quick Ratio Range
Min: 1.88   Max: 106.93
Current: 4.31

1.88
106.93
Days Inventory 435.16
KERX's Days Inventory is ranked higher than
77% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. KERX: 435.16 )
KERX' s 10-Year Days Inventory Range
Min: 0   Max: 0
Current: 435.16

Days Sales Outstanding 5.37
KERX's Days Sales Outstanding is ranked higher than
97% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. KERX: 5.37 )
KERX' s 10-Year Days Sales Outstanding Range
Min: 0.51   Max: 2248.5
Current: 5.37

0.51
2248.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.30
KERX's Price/Net Cash is ranked higher than
80% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 55.00 vs. KERX: 13.30 )
KERX' s 10-Year Price/Net Cash Range
Min: 1.09   Max: 29.11
Current: 13.3

1.09
29.11
Price/Net Current Asset Value 13.20
KERX's Price/Net Current Asset Value is ranked higher than
79% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 31.07 vs. KERX: 13.20 )
KERX' s 10-Year Price/Net Current Asset Value Range
Min: 1.07   Max: 29.11
Current: 13.2

1.07
29.11
Price/Tangible Book 12.60
KERX's Price/Tangible Book is ranked higher than
69% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. KERX: 12.60 )
KERX' s 10-Year Price/Tangible Book Range
Min: 0.93   Max: 26.2
Current: 12.6

0.93
26.2
Price/Median PS Value 1.30
KERX's Price/Median PS Value is ranked higher than
80% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. KERX: 1.30 )
KERX' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 21.47
Current: 1.3

0.02
21.47
Earnings Yield (Greenblatt) -8.20
KERX's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. KERX: -8.20 )
KERX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -8.2   Max: 27616.5
Current: -8.2

-8.2
27616.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:KYX.Germany,
Keryx Biopharmaceuticals, Inc., was incorporated in Delaware in October 1998. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of renal disease. It is developing ZerenexTM an oral, ferric iron-based compound. It has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease, or CKD, on dialysis, conducted pursuant to a Special Protocol Assessment, or SPA, agreement with the U.S. Food and Drug Administration, or FDA. Its New Drug Application, or NDA, is currently under review by the FDA with an assigned Prescription Drug User Fee Act, or PDUFA. It has also completed a U.S.-based Phase 2 study of Zerenex for the management of elevated serum phosphorus levels and iron deficiency anemia in subjects with Stage 3 to 5 NDD-CKD. Currently, its only drug candidate is Zerenex. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.
» More Articles for KERX

Headlines

Articles On GuruFocus.com
me Jan 23 2015 
Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX Dec 05 2014 
Baupost’s Seth Klarman Buys Cheniere Energy, Ocwen Financial, Antero Resources, Sells Boyd Gaming, Nov 14 2014 
Seth Klarman’s The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, Sel Aug 14 2014 
Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD Mar 24 2014 
Weekly Insider Sells Highlight: FLT, KERX, KOG, MEI, HTZ Jan 06 2014 
comment on KERX Mar 02 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 

More From Other Websites
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 27 2015
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog Jan 22 2015
Keryx Biopharmaceuticals (KERX) in Focus: Stock Falls by 6.8% - Tale of the Tape Jan 22 2015
Keryx Biopharmaceuticals, Inc. Announces Pricing of $110 Million Public Offering of Common Stock Jan 21 2015
Keryx Biopharmaceuticals, Inc. Announces $100 Million Proposed Public Offering of Common Stock Jan 20 2015
Keryx Biopharmaceuticals, Inc. Announces $100 Million Proposed Public Offering of Common Stock Jan 20 2015
Dyadic Appoints Michael Tarnok As Chairman Of The Board Of Directors Jan 12 2015
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 12 2015
Big deals, data kick off JPMorgan health conference Jan 12 2015
Keryx Biopharmaceuticals Announces Transition of Leadership Jan 11 2015
Keryx Biopharmaceuticals Announces Transition of Leadership Jan 11 2015
Keryx Biopharmaceuticals Shares May Hit $25 Jan 08 2015
Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product... Jan 08 2015
UPDATE: MLV & Co Raises PT On Keryx Biopharmaceuticals On Additional Auryxia Growth Potential Jan 07 2015
Keryx Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
Keryx Biopharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 07 2015
Keryx drug for dialysis patients poised to challenge Genzyme Dec 30 2014
Keryx Biopharmaceuticals Announces Commercial Launch of AURYXIA™ (ferric citrate) Tablets in the... Dec 22 2014
Keryx Biopharmaceuticals Announces Commercial Launch of AURYXIA(TM) (ferric citrate) Tablets in the... Dec 22 2014
Keryx Biopharmaceuticals Announces Commercial Launch of AURYXIA(TM) (ferric citrate) Tablets in the... Dec 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK